Merck + Co., Inc.

Iyassu K Sebhat

Ravi P Nargund

Zhixiong Ye

Liangqin Guo

Raman Kumar Bakshi

Khaled J Barakat

Feroze Ujjainwalla

Brenda L Palucki

Yingjie Lai

Arthur A Patchett

Jonathan R Young

Min K Park

Patrick G Pollard

Thomas F Walsh

Mark T Goulet

Shuwen He

Jian Liu

Leonardus H T Van Der Ploeg

Tianying Jian

Qingmei Hong

Daniel Warner

Certain novel N-acylated spiropiperidine derivatives are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity, diabetes, sexual dysfunction, including erectile dysfunction and female sexual dysfunction.

Acylated spiropiperidine derivatives as melanocortin-4 receptor agonists

Certain novel N-acylated piperazine derivatives are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity, diabetes, sexual dysfunction, including erectile dysfunction and female sexual dysfunction.

Acylated piperazine derivatives as melanocortin-4 receptor agonists

Certain novel bridged piperidine derivatives are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity, diabetes, sexual dysfunction, including erectile dysfunction and female sexual dysfunction.

Bridged piperidine derivatives as melanocortin receptor agonists

Certain novel-substituted N-acylated piperidine derivatives are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-receptor (MC-R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-R, such as obesity, diabetes, sexual dysfunction, including erectile dysfunction and female sexual dysfunction.

Acylated piperidine derivatives as melanocortin-4 receptor agonists

Certain novel 4-substituted piperidine compounds are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity, diabetes, sexual dysfunction, including erectile dysfunction and female sexual dysfunction.

Substituted piperidines as melanocortin receptor agonists

Certain novel substituted piperidine compounds are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment and control of obesity, diabetes, and sexual dysfunction, including erectile dysfunction and female sexual dysfunction.

Certain novel substituted piperidine compounds are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity, diabetes, sexual dysfunction, including erectile dysfunction and female sexual dysfunction. Also provided are methods of treating sexual dysfunction with a compound that is a selective agonist of MC-4R over any other human melanocortin receptor.

Substituted piperidines as melanocortin-4 receptor agonists

Growing community of inventors

New York, NY, United States of America

Iyassu K Sebhat